Best practices for assessing and reporting tobacco use in urology oncology practice and research

Urol Oncol. 2021 Aug;39(8):446-451. doi: 10.1016/j.urolonc.2021.04.033. Epub 2021 May 31.

Abstract

Tobacco use is the cause of several urologic cancers. Persistent use after diagnosis is associated with worse cancer-specific, quality of life, and overall mortality outcomes. Cigarette smoking remains the most common form of tobacco use despite significant population-level decline over the past few decades. The burden of smoking-related urologic disease is under appreciated by urologists and patients which has resulted in gaps in clinical care and limitations to research progress. We sought to summarize evidence-based practices and guideline recommendations for assessing and reporting tobacco use in the clinical and research settings. With a focus on smoking, our two primary goals are: 1) to promote the adoption of standardized and validated measures of tobacco use and 2) to highlight evidence-based strategies for urologists to use in clinical practice.

Keywords: Bladder cancer; Smoking cessation, Cancer diagnosis, Nicotine dependence.

Publication types

  • Review

MeSH terms

  • Biomedical Research / standards*
  • Delivery of Health Care / standards*
  • Guideline Adherence
  • Humans
  • Medical Oncology / standards*
  • Practice Guidelines as Topic / standards*
  • Smoking Cessation / methods*
  • Tobacco Use / adverse effects*
  • Urologic Neoplasms / etiology
  • Urologic Neoplasms / prevention & control*